This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n4http://linked.opendata.cz/resource/drugbank/drug/DB04222/identifier/pubchem-compound/
n7http://linked.opendata.cz/resource/drugbank/drug/DB04222/identifier/pubchem-substance/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04222/identifier/drugbank/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB04222/identifier/pdb/

Statements

Subject Item
n2:DB04222
rdf:type
n5:Drug
n5:description
An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]
n5:group
experimental
owl:sameAs
n12:DB04222 n13:DB04222
dcterms:title
Sparsomycin
adms:identifier
n4:9543443 n7:46505251 n8:DB04222 n9:SPS
n5:synthesisReference
Henricus C. J. Ottenheijm, "Sparsomycin (SC-RS) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (SC-RS) compounds." U.S. Patent US4820712, issued April, 1986.
n5:IUPAC-Name
n6:271B45BF-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B45C5-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B45C4-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B45C1-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B45C2-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B45C3-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B45BD-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B45BB-363D-11E5-9242-09173F13E4C5 n6:271B45BE-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B45BC-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B45CB-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B45CC-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B45C6-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B45C7-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B45C9-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B45C8-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B45CA-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B45D1-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B45D3-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B45D4-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B45D0-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B45CF-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B45D2-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B45C0-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B45CD-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B45CE-363D-11E5-9242-09173F13E4C5